The U.S. Department of Justice reached a non-prosecution agreement with Alibaba Group and its U.S.-based payment processor, AUS Merchant Services, concluding a significant investigation into illegal drug distribution without filing criminal charges. This resolution follows allegations that Alibaba's platforms facilitated approximately 80,000 unlawful sales of pharmaceuticals and related contraband imported into the United States over several years.
Federal prosecutors detailed how between 2016 and 2024, merchants on Alibaba.com and AliExpress.com shipped controlled substances, counterfeit drugs, listed chemicals, and pill presses into the U.S. Law enforcement officials conducted more than 40 undercover purchases to document the illicit trade. Despite this extensive evidence, the agreement allowed Alibaba and AUS to avoid convictions by acknowledging responsibility, agreeing to a monetary settlement, and committing to improved compliance measures.
The case highlights challenges in regulating multinational e-commerce platforms that connect sellers and buyers across borders. Recorded internal concerns within Alibaba revealed weaknesses in their compliance controls and monitoring systems, with some merchants circumventing platform rules by shifting conversations to external messaging apps to facilitate illegal sales.
This outcome reflects a recent pattern within the Justice Department of opting for settlements rather than criminal prosecutions in complex corporate cases involving drug safety and import violations. The resolution serves as both a public acknowledgment of the scale of unauthorized pharmaceutical sales enabled by major online marketplaces and a signal to enforce stricter controls moving forward, all while stopping short of formal criminal penalties.